Cargando…

Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is characterized by increased left ventricular wall thickness, cardiomyocyte hypertrophy, and fibrosis. Adverse cardiac risk characterization has been performed using late gadolinium enhancement (LGE), native T1, and extracellular volume (ECV). Relaxatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Elizabeth W., Kamesh Iyer, Srikant, Solomon, Michael P., Li, Zhaohuan, Zhang, Qiang, Piechnik, Stefan, Werys, Konrad, Swago, Sophia, Moon, Brianna F., Rodgers, Zachary B., Hall, Anya, Kumar, Rishabh, Reza, Nosheen, Kim, Jessica, Jamil, Alisha, Desjardins, Benoit, Litt, Harold, Owens, Anjali, Witschey, Walter R. T., Han, Yuchi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543937/
https://www.ncbi.nlm.nih.gov/pubmed/34689798
http://dx.doi.org/10.1186/s12968-021-00813-5
_version_ 1784589714285658112
author Thompson, Elizabeth W.
Kamesh Iyer, Srikant
Solomon, Michael P.
Li, Zhaohuan
Zhang, Qiang
Piechnik, Stefan
Werys, Konrad
Swago, Sophia
Moon, Brianna F.
Rodgers, Zachary B.
Hall, Anya
Kumar, Rishabh
Reza, Nosheen
Kim, Jessica
Jamil, Alisha
Desjardins, Benoit
Litt, Harold
Owens, Anjali
Witschey, Walter R. T.
Han, Yuchi
author_facet Thompson, Elizabeth W.
Kamesh Iyer, Srikant
Solomon, Michael P.
Li, Zhaohuan
Zhang, Qiang
Piechnik, Stefan
Werys, Konrad
Swago, Sophia
Moon, Brianna F.
Rodgers, Zachary B.
Hall, Anya
Kumar, Rishabh
Reza, Nosheen
Kim, Jessica
Jamil, Alisha
Desjardins, Benoit
Litt, Harold
Owens, Anjali
Witschey, Walter R. T.
Han, Yuchi
author_sort Thompson, Elizabeth W.
collection PubMed
description BACKGROUND: Hypertrophic cardiomyopathy (HCM) is characterized by increased left ventricular wall thickness, cardiomyocyte hypertrophy, and fibrosis. Adverse cardiac risk characterization has been performed using late gadolinium enhancement (LGE), native T1, and extracellular volume (ECV). Relaxation time constants are affected by background field inhomogeneity. T1ρ utilizes a spin-lock pulse to decrease the effect of unwanted relaxation. The objective of this study was to study T1ρ as compared to T1, ECV, and LGE in HCM patients. METHODS: HCM patients were recruited as part of the Novel Markers of Prognosis in Hypertrophic Cardiomyopathy study, and healthy controls were matched for comparison. In addition to cardiac functional imaging, subjects underwent T1 and T1ρ cardiovascular magnetic resonance imaging at short-axis positions at 1.5T. Subjects received gadolinium and underwent LGE imaging 15–20 min after injection covering the entire heart. Corresponding basal and mid short axis LGE slices were selected for comparison with T1 and T1ρ. Full-width half-maximum thresholding was used to determine the percent enhancement area in each LGE-positive slice by LGE, T1, and T1ρ. Two clinicians independently reviewed LGE images for presence or absence of enhancement. If in agreement, the image was labeled positive (LGE + +) or negative (LGE −−); otherwise, the image was labeled equivocal (LGE + −). RESULTS: In 40 HCM patients and 10 controls, T1 percent enhancement area (Spearman’s rho = 0.61, p < 1e-5) and T1ρ percent enhancement area (Spearman’s rho = 0.48, p < 0.001e-3) correlated with LGE percent enhancement area. T1 and T1ρ percent enhancement areas were also correlated (Spearman’s rho = 0.28, p = 0.047). For both T1 and T1ρ, HCM patients demonstrated significantly longer relaxation times compared to controls in each LGE category (p < 0.001 for all). HCM patients also showed significantly higher ECV compared to controls in each LGE category (p < 0.01 for all), and LGE −− slices had lower ECV than LGE + + (p = 0.01). CONCLUSIONS: Hyperenhancement areas as measured by T1ρ and LGE are moderately correlated. T1, T1ρ, and ECV were elevated in HCM patients compared to controls, irrespective of the presence of LGE. These findings warrant additional studies to investigate the prognostic utility of T1ρ imaging in the evaluation of HCM patients.
format Online
Article
Text
id pubmed-8543937
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85439372021-10-25 Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy Thompson, Elizabeth W. Kamesh Iyer, Srikant Solomon, Michael P. Li, Zhaohuan Zhang, Qiang Piechnik, Stefan Werys, Konrad Swago, Sophia Moon, Brianna F. Rodgers, Zachary B. Hall, Anya Kumar, Rishabh Reza, Nosheen Kim, Jessica Jamil, Alisha Desjardins, Benoit Litt, Harold Owens, Anjali Witschey, Walter R. T. Han, Yuchi J Cardiovasc Magn Reson Research BACKGROUND: Hypertrophic cardiomyopathy (HCM) is characterized by increased left ventricular wall thickness, cardiomyocyte hypertrophy, and fibrosis. Adverse cardiac risk characterization has been performed using late gadolinium enhancement (LGE), native T1, and extracellular volume (ECV). Relaxation time constants are affected by background field inhomogeneity. T1ρ utilizes a spin-lock pulse to decrease the effect of unwanted relaxation. The objective of this study was to study T1ρ as compared to T1, ECV, and LGE in HCM patients. METHODS: HCM patients were recruited as part of the Novel Markers of Prognosis in Hypertrophic Cardiomyopathy study, and healthy controls were matched for comparison. In addition to cardiac functional imaging, subjects underwent T1 and T1ρ cardiovascular magnetic resonance imaging at short-axis positions at 1.5T. Subjects received gadolinium and underwent LGE imaging 15–20 min after injection covering the entire heart. Corresponding basal and mid short axis LGE slices were selected for comparison with T1 and T1ρ. Full-width half-maximum thresholding was used to determine the percent enhancement area in each LGE-positive slice by LGE, T1, and T1ρ. Two clinicians independently reviewed LGE images for presence or absence of enhancement. If in agreement, the image was labeled positive (LGE + +) or negative (LGE −−); otherwise, the image was labeled equivocal (LGE + −). RESULTS: In 40 HCM patients and 10 controls, T1 percent enhancement area (Spearman’s rho = 0.61, p < 1e-5) and T1ρ percent enhancement area (Spearman’s rho = 0.48, p < 0.001e-3) correlated with LGE percent enhancement area. T1 and T1ρ percent enhancement areas were also correlated (Spearman’s rho = 0.28, p = 0.047). For both T1 and T1ρ, HCM patients demonstrated significantly longer relaxation times compared to controls in each LGE category (p < 0.001 for all). HCM patients also showed significantly higher ECV compared to controls in each LGE category (p < 0.01 for all), and LGE −− slices had lower ECV than LGE + + (p = 0.01). CONCLUSIONS: Hyperenhancement areas as measured by T1ρ and LGE are moderately correlated. T1, T1ρ, and ECV were elevated in HCM patients compared to controls, irrespective of the presence of LGE. These findings warrant additional studies to investigate the prognostic utility of T1ρ imaging in the evaluation of HCM patients. BioMed Central 2021-10-25 /pmc/articles/PMC8543937/ /pubmed/34689798 http://dx.doi.org/10.1186/s12968-021-00813-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Thompson, Elizabeth W.
Kamesh Iyer, Srikant
Solomon, Michael P.
Li, Zhaohuan
Zhang, Qiang
Piechnik, Stefan
Werys, Konrad
Swago, Sophia
Moon, Brianna F.
Rodgers, Zachary B.
Hall, Anya
Kumar, Rishabh
Reza, Nosheen
Kim, Jessica
Jamil, Alisha
Desjardins, Benoit
Litt, Harold
Owens, Anjali
Witschey, Walter R. T.
Han, Yuchi
Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy
title Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy
title_full Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy
title_fullStr Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy
title_full_unstemmed Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy
title_short Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy
title_sort endogenous t1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543937/
https://www.ncbi.nlm.nih.gov/pubmed/34689798
http://dx.doi.org/10.1186/s12968-021-00813-5
work_keys_str_mv AT thompsonelizabethw endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT kameshiyersrikant endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT solomonmichaelp endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT lizhaohuan endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT zhangqiang endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT piechnikstefan endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT weryskonrad endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT swagosophia endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT moonbriannaf endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT rodgerszacharyb endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT hallanya endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT kumarrishabh endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT rezanosheen endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT kimjessica endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT jamilalisha endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT desjardinsbenoit endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT littharold endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT owensanjali endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT witscheywalterrt endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy
AT hanyuchi endogenoust1rcardiovascularmagneticresonanceinhypertrophiccardiomyopathy